# Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies

> **NCT00593554** · PHASE2 · TERMINATED · sponsor: **Sherif S. Farag** · enrollment: 9 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Acute Lymphoblastic Leukemia
- Myelodysplasia
- Chronic Myeloid Leukemia

## Interventions

- **RADIATION:** Total Body Irradiation
- **DRUG:** Thiotepa
- **DRUG:** Fludarabine
- **BIOLOGICAL:** Rabbit ATG
- **DRUG:** Palifermin

## Key facts

- **NCT ID:** NCT00593554
- **Lead sponsor:** Sherif S. Farag
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-08-07
- **Primary completion:** 2016-08-27
- **Final completion:** 2017-07-28
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Slow accrual
- **Last updated:** 2018-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00593554

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00593554, "Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00593554. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*